Which drug tames skin vasculitis best? new trial aims to find out

NCT ID NCT02939573

Recruiting now Disease control Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests three standard medications—colchicine, dapsone, and azathioprine—in 90 people with isolated skin vasculitis (inflammation of small or medium blood vessels in the skin). Participants are randomly assigned to one of the drugs, and doctors track how well the skin responds over 12 months. The goal is to see which drug works best to control the condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: colchicine, dapsone, or azathioprine
What this could lead to: If successful, this trial could identify which of these three existing drugs works best for controlling skin vasculitis, helping doctors choose the most effective treatment.
What could go wrong: This is a phase 2 trial with only 90 participants, so results may not apply to everyone. The drugs have known side effects, and the study may not find a clear winner.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous leukocytoclastic angiitis cutaneous polyarteritis nodosa cutaneous vasculitis immunoglobulin A vasculitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUTANEOUS POLYARTERITIS NODOSA HENOCH-SCHÖNLEIN PURPURA IGA VASCULITIS PRIMARY CUTANEOUS VASCULITIS

Contacts and locations

Locations

Boston University School of Medicine
COMPLETED

Boston, Massachusetts, 02118, United States
Cleveland Clinic
COMPLETED

Cleveland, Ohio, United States
Hospital for Special Surgery
COMPLETED

New York, New York, 10021, United States
Mayo Clinic
COMPLETED

Rochester, Minnesota, 55905, United States
McGill University Health Centre
RECRUITING

Montreal, Quebec, H4A 3J1, Canada
Northwell Health
COMPLETED

Lake Success, New York, 11042, United States
Penn State Hershey Medical Center
COMPLETED

Hershey, Pennsylvania, 17033, United States
St. Joseph's Healthcare
RECRUITING

Hamilton, Ontario, Canada
Tohoku Medical and Pharmaceutical University Hospital
COMPLETED

Kyoto, 602-8566, Japan
UT Southwestern Medical Center
RECRUITING

Dallas, Texas, 75390, United States
University of Kansas Medical Center
RECRUITING

Kansas City, Kansas, United States
University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
University of Toronto Mount Sinai Hospital
RECRUITING

Toronto, Ontario, Canada
University of Utah
COMPLETED

Salt Lake City, Utah, United States
University of Virginia
RECRUITING

Charlottesville, Virginia, 22903, United States
Vanderbilt University
RECRUITING

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.